Wholesalers Drawing DoJ Scrutiny In Drug Diversion Investigations
Executive Summary
Wholesalers will face increasing Justice Department scrutiny in pharmaceutical diversion cases, a federal prosecutor predicted
You may also be interested in...
Spitzer squeezing secondary market
Cardinal Health is the first wholesaler to settle with the New York Attorney General's office regarding trading in the secondary wholesale market. According to the AG's office, Cardinal bought and sold drugs in the secondary market without appropriate regard for drug integrity and risk of diversion. Under the settlement, Cardinal agrees to pay $10 million and adopt a set of Wholesaler Safe Product Practices. The investigation into improper trading practices of other wholesalers will continue, the AG says. AmerisourceBergen and McKesson have also been subpoenaed as part of the investigation (1"The Pink Sheet" April 18, 2005, p. 23). Wholesaler distribution practices that allow drug diversion may emerge as a focus of prosecution at the federal level as well (2"The Pink Sheet" Dec. 12, 2005, p. 25)...
Spitzer squeezing secondary market
Cardinal Health is the first wholesaler to settle with the New York Attorney General's office regarding trading in the secondary wholesale market. According to the AG's office, Cardinal bought and sold drugs in the secondary market without appropriate regard for drug integrity and risk of diversion. Under the settlement, Cardinal agrees to pay $10 million and adopt a set of Wholesaler Safe Product Practices. The investigation into improper trading practices of other wholesalers will continue, the AG says. AmerisourceBergen and McKesson have also been subpoenaed as part of the investigation (1"The Pink Sheet" April 18, 2005, p. 23). Wholesaler distribution practices that allow drug diversion may emerge as a focus of prosecution at the federal level as well (2"The Pink Sheet" Dec. 12, 2005, p. 25)...
Daytrana Post-Marketing Study Of Skin Sensitization Urged By Committee
Post-marketing surveillance and study of skin sensitization with Shire/Noven's Daytrana methylphenidate patch for attention deficit/hyperactivity disorder were recommended by FDA's Psychopharmacologic Drugs Advisory Committee at its Dec. 2 meeting